College of Medicine, Physiology Department, King Saud University, Saudi Arabia.
Therapeutic Chemistry Department, National Research Center, Cairo, Egypt; Biochemistry Department, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Life Sci. 2021 Jul 15;277:119512. doi: 10.1016/j.lfs.2021.119512. Epub 2021 Apr 16.
Tamoxifen (TAMO) is a chemotherapeutic drug used for the treatment of breast cancer. Nevertheless, there is a lack of information available in regarding its nephrotoxicity. The purpose of this work was to investigate the impact of cyanocobalamin (COB) and/or calcitriol (CAL) injections on TAMO-induced nephrotoxicity.
Animals were allocated into five groups as follows: normal control group; TAMO (45 mg/kg) administered group; TAMO+COB (6mg/kg, i.p) treated group; TAMO+CAL (0.3 μg/kg, i.p) treated group; TAMO+COB+CAL combination groups.
Renal injury induced by TAMO was confirmed by the alteration in renal function parameters in the serum (urea and creatinine), as well as in the urine (creatinine clearance, total protein and albumin). These results were supported by histopathological examination. Upregulation of renal inflammatory parameters; tumor necrosis factor (TNF)-α, interleukin (IL)-6, C-reactive protein (CRP); and transforming growth factor (TGF)-β1 as well as in protein expression of nuclear factor-kappa B (NF-κB) and cleaved caspase-3 were observed to a greater extent in the TAMO-treated rats compared with the control. Renal fibrosis was also evidenced by a elevation in renal L-hydroxyproline level as well as by histomorphological collagen deposition in TAMO-treated groups compared to the control group. Administration of COB and/or CAL concurrently with TAMO significantly ameliorated the deviation in the above-studied parameters and improved the histopathological renal picture.
Inhibition of NF-κβ-mediated inflammation and caspase-3-induced apoptosis are possible renoprotective mechanisms of COB and/or CAL against TAMO nephrotoxicity, which was more noticeable in the TAMO group treated with the combination of the two vitamins in question.
他莫昔芬(TAMO)是一种用于治疗乳腺癌的化疗药物。然而,关于其肾毒性的信息却很缺乏。本研究的目的是探讨氰钴胺(COB)和/或骨化三醇(CAL)注射对 TAMO 诱导的肾毒性的影响。
动物被分为五组:正常对照组;TAMO(45mg/kg)给药组;TAMO+COB(6mg/kg,腹腔注射)治疗组;TAMO+CAL(0.3μg/kg,腹腔注射)治疗组;TAMO+COB+CAL 联合组。
TAMO 引起的肾损伤通过血清(尿素和肌酐)和尿液(肌酐清除率、总蛋白和白蛋白)中肾功能参数的改变得到证实。这些结果得到了组织病理学检查的支持。与对照组相比,TAMO 治疗的大鼠肾组织中炎症参数肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6、C 反应蛋白(CRP)和转化生长因子(TGF)-β1 的表达上调,核因子-kappa B(NF-κB)和裂解半胱天冬酶-3 的蛋白表达也上调。与对照组相比,TAMO 治疗组肾羟脯氨酸水平升高,组织形态学胶原沉积增加,表明肾纤维化。与 TAMO 组相比,同时给予 COB 和/或 CAL 可显著改善上述参数的偏差,并改善组织病理学肾脏图像。
NF-κβ 介导的炎症和 caspase-3 诱导的细胞凋亡的抑制可能是 COB 和/或 CAL 对 TAMO 肾毒性的肾保护机制,在联合使用这两种维生素的 TAMO 组中更为明显。